The volatility ratio for the week is 11.35%, and the volatility levels for the past 30 days are 9.69% for BCAX. The simple moving average for the past 20 days is -5.99% for BCAX’s stock, with a -10.03% simple moving average for the past 200 days.
Is It Worth Investing in Bicara Therapeutics Inc (NASDAQ: BCAX) Right Now?
Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCAX is 32.53M, and currently, short sellers hold a 5.20% ratio of that floaft. The average trading volume of BCAX on November 27, 2024 was 459.06K shares.
BCAX) stock’s latest price update
The stock price of Bicara Therapeutics Inc (NASDAQ: BCAX) has jumped by 12.05 compared to previous close of 18.25. Despite this, the company has seen a gain of 5.85% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters’ option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
Analysts’ Opinion of BCAX
Many brokerage firms have already submitted their reports for BCAX stocks, with Rodman & Renshaw repeating the rating for BCAX by listing it as a “Buy.” The predicted price for BCAX in the upcoming period, according to Rodman & Renshaw is $48 based on the research report published on November 05, 2024 of the current year 2024.
Stifel gave a rating of “Buy” to BCAX, setting the target price at $47 in the report published on October 08th of the current year.
BCAX Trading at -9.42% from the 50-Day Moving Average
After a stumble in the market that brought BCAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.20% of loss for the given period.
Volatility was left at 9.69%, however, over the last 30 days, the volatility rate increased by 11.35%, as shares sank -13.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.46% lower at present.
During the last 5 trading sessions, BCAX rose by +5.85%, in comparison to the 20-day moving average, which settled at $21.75. In addition, Bicara Therapeutics Inc saw -12.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAX starting from RA CAPITAL MANAGEMENT, L.P., who purchase 1,833,000 shares at the price of $18.00 back on Sep 16 ’24. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 4,303,418 shares of Bicara Therapeutics Inc, valued at $32,994,000 using the latest closing price.
Flynn James E, the Possible Members of 10% Group of Bicara Therapeutics Inc, purchase 70,000 shares at $18.00 during a trade that took place back on Sep 17 ’24, which means that Flynn James E is holding 897,587 shares at $1,260,000 based on the most recent closing price.
Stock Fundamentals for BCAX
The liquidity ratio also appears to be rather interesting for investors as it stands at 36.01.
Conclusion
In a nutshell, Bicara Therapeutics Inc (BCAX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
